89bio Inc (ETNB) Stock
ETNB is no longer traded. 89bio was acquired by Roche in October 2025.
Each ETNB share was exchanged for $14.50 in cash plus a contingent value right of up to $6.00. Prices on this page are historical; the last trade was October 28, 2025 at $14.84.
89bio stock price history
ETNB final trading statistics
- Final close
- $14.84
- Final trading day
- Oct 28, 2025
- Market cap at delisting
- $2.20B
- Shares outstanding
- 148.49M
- Final 52-week range
- $4.16 – $15.06
- Avg. volume (final 3 mo.)
- 4,543,559
- All-time high (split-adj.)
- $41.77 · Mar 2020
- All-time low (split-adj.)
- $2.09 · May 2022
- Return since IPO
- -28.7%
- Beta
- 1.26
- Book value / share
- $3.52
- Price / book
- 4.22
89bio annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$367.1M | -$3.43 |
| FY2023 | $0.00 | -$142.2M | -$2.01 |
| FY2022 | $0.00 | -$102.0M | -$3.54 |
| FY2021 | $0.00 | -$90.1M | -$4.48 |
| FY2020 | $0.00 | -$49.5M | -$3.10 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
89bio stock FAQ
What happened to 89bio stock?
89bio was acquired by Roche in October 2025. Shareholders received $14.50 in cash plus a contingent value right of up to $6.00 for each share. ETNB stock stopped trading on the Nasdaq, with a final close of $14.84 on October 28, 2025.
What did 89bio shareholders receive?
Each ETNB share was converted into $14.50 in cash plus a contingent value right of up to $6.00. The deal was valued at up to about $3.5 billion.
Is ETNB stock still trading?
No. ETNB was delisted from the Nasdaq in October 2025 and no longer trades on a U.S. exchange.
What was the last price of ETNB stock?
ETNB closed at $14.84 on its final trading day, October 28, 2025, for a market value of about $2.20B.
What were 89bio's revenue and earnings in its last full fiscal year?
89bio reported revenue of $0.00 and net income of -$367.1M in fiscal 2024, its last full year as a public company.
When did 89bio go public?
89bio Inc stock began trading on November 11, 2019.